Cancer Research

Stanford Flips a Lymphoma Protein Into a Cancer Kill Switch

Stanford Medicine researchers engineered a small molecule called TCIP3 that grabs BCL6, a protein that keeps lymphoma cells alive by silencing death-related genes, and redirects it to do the opposite: activating the cell's own self-destruct machinery. In mice, twice-daily treatment eliminated aggressive human lymphoma tumors within 11 days. The strategy, called chemically induced proximity, connects BCL6 to proteins P300 and CBP, which add chemical tags that switch death genes on rather than off. The team believes this molecular rewiring approach could extend beyond lymphoma to other cancers and even autoimmune diseases. Human trials remain years away, but the findings represent a meaningful shift from simply blocking cancer-promoting proteins to actively weaponizing them.